ArticleApplied biochemistry and biotechnology2026
Knocking Down CDKN2A Enhances the Therapeutic Effects of Metformin and Resveratrol on Diabetic Retinopathy.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic retinopathy (DR) is a major vision-threatening complication of diabetes. Although cyclin-dependent kinase inhibitor 2 A (CDKN2A) is linked to glucose dysregulation and diabetes risk, its role in DR remains unclear. Therefore, this study aimed to investigate whether knockdown of CDKN2A can enhance the therapeutic effects of metformin (Met) and resveratrol (RSV) in ameliorating DR progression. A DR model was established in rats by streptozotocin (STZ) induction, and an in vitro DR model was constructed using high glucose (HG)-treated adult retinal pigment epithelial cell line-19 (ARPE-19) cells. The expression of CDKN2A was examined by Western blotting, immunohistochemistry, and immunofluorescence. Cell injury was assessed via a cell counting kit-8 (CCK-8) assay and flow cytometry. Mitochondrial damage was evaluated via MitoSOX Red staining and JC-1 staining. Retinal histopathological changes were observed through hematoxylin and eosin (H&E) staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. The N6-methyladenosine (m6A) modification level of CDKN2A was detected by chromatin immunoprecipitation quantitative polymerase chain reaction (ChIP-qPCR). The results showed that in both the DR rat model and HG-treated ARPE-19 cells, the expression of CDKN2A and methyltransferase-like 3 (METTL3) was significantly upregulated. Knockdown of CDKN2A alone did not significantly alter DR progression in rats or HG‑induced cell injury, whereas overexpression of CDKN2A further exacerbated pathological outcomes. Treatment with Met or RSV alleviated retinal damage and HG-induced cell injury, which was associated with improved mitochondrial function, as evidenced by increased mitochondrial membrane potential and adenosine triphosphate (ATP) levels and decreased mitochondrial reactive oxygen species (mROS) levels. Notably, the therapeutic effects of Met and RSV were significantly enhanced when combined with CDKN2A knockdown. Furthermore, Met and RSV act through METTL3 to exert dual regulatory effects. On the one hand, they suppressed the m6A methylation and expression of CDKN2A in a METTL3-dependent manner. On the other hand, the improvement in mitochondrial function induced by Met and RSV also involved METTL3-mediated regulation. Together, these processes formed a reinforcing cycle in which Met and RSV inhibited CDKN2A expression, and the resulting downregulation of CDKN2A further enhanced the therapeutic efficacy of both agents in mitigating DR progression.This study revealed that knockdown of CDKN2A expression significantly enhanced the therapeutic effects of Met and RSV on DR and that these drugs simultaneously regulated CDKN2A expression and improved mitochondrial function through METTL3. The role of CDKN2A in DR is not directly pathogenic; rather, it serves as a key sensitizer for drug treatment.
Indexed as
Identifiers
41843007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.